Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Send this study to a contact
1
Your personal information
Your name
Your e-mail
Send me a copy
2
Your recipient's information
The name of your contact
Your contact email
3
Your message
Votre message
A phase IV, open, multicentric study to evaluate the immune response to a hepatitis B challenge dose in healthy subjects, 72 to 78 months after they received a primary vaccination course of GSK Biologicals’ Engerix™-B (thiomersal-free 20 µg or preservative-free 10 µg) vaccine, in the primary study HBV-280 https://kusajili.com:443/Trial/Lel2x3RuwEG9IrRKmm6htw%24a-phase-iv-open-multicentric-study-to-evaluate-the-immune-response-to-a-hepatitis-b-challenge-dose-in-healthy-subjects-72-to-78
I have read and accept the terms of use of the site and the Privacy Policy
Send your message